Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib and Benmelstobart in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT07904819Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2026
- Primary completion
- Dec 2030
01
Overview
A Phase 2 trial of anlotinib, benmelstobart in nasopharyngeal carcinoma (NPC), sponsored by Sun Yat-sen University. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
anlotinibbenmelstobart
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT07904819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07904819.